NYDFS completed its first investigation by the new Office of Pharmacy Benefits regarding a price spike. According to NYDFS findings: “Cipla has entered into an agreement with OPB to put in place new internal controls governing the reporting of drug prices and will report on the implementation and maintenance of those new controls in one year. OPB’s investigation confirmed that no consumers were impacted by the apparent price increase but uncovered errors in reporting of drug pricing that if left unaddressed had the potential to cause serious issues in the future.”
The report of investigation can be found here: https://www.dfs.ny.gov/reports_and_publications/press_releases/pr202202011